Publications

Wang, C; Tu, Z; Cai, X; Wang, W; Davis, AK; Nattamai, K; Paranjpe, A; Dexheimer, P; Wu, J; Huang, FL; et al. A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation. Blood Advances. 2023; 7:2590-2605.

Doherty, AC; Huddleston, DA; Horn, PS; Ratner, N; Simpson, BN; Schorry, EK; Aschbacher-Smith, L; Prada, CE; Gilbert, DL. Motor Function and Physiology in Youth With Neurofibromatosis Type 1. Pediatric Neurology. 2023; 143:34-43.

Jackson, M; Ahmari, N; Wu, J; Rizvi, TA; Fugate, E; Kim, MO; Dombi, E; Arnhof, H; Boehmelt, G; Düchs, MJ; et al. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. The Journal of pharmacology and experimental therapeutics. 2023; 385:106-116.

Ratner, N; Hu, L; Pundavela, J; Epstein, JA. Abstract IA17: Use of RAS isoforms in nerve tumors. Molecular cancer research : MCR. 2023; 21:ia17.

Na, Y; Hall, A; Yu, Y; Hu, L; Choi, K; Burgard, JA; Szabo, S; Huang, G; Ratner, N; Wu, J. Runx1/3-driven adaptive endoplasmic reticulum stress pathways contribute to neurofibromagenesis. Oncogene: Including Oncogene Reviews. 2023; 42:1038-1047.

Hennigan, RF; Thomson, CS; Stachowski, K; Nassar, N; Ratner, N. Merlin tumor suppressor function is regulated by PIP2-mediated dimerization. Editor, van der Wel P. PloS one. 2023; 18:e0281876.

Magallón-Lorenz, M; Terribas, E; Ortega-Bertran, S; Creus-Bachiller, E; Fernández, M; Requena, G; Rosas, I; Mazuelas, H; Uriarte-Arrazola, I; Negro, A; et al. Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis. iScience. 2023; 26:106096.

Kershner, LJ; Choi, K; Wu, J; Zhang, X; Perrino, M; Salomonis, N; Shern, JF; Ratner, N. Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment. JCI insight. 2022; 7:e154513.

González-Muñoz, T; Kim, AR; Ratner, N; Peinado, H. The Need for New Treatments Targeting MPNST: The Potential of Strategies Combining MEK Inhibitors with Antiangiogenic Agents. Clinical Cancer Research. 2022; 28:3185-3195.

Cram, JP; Wu, J; Coover, RA; Rizvi, TA; Chaney, KE; Ravindran, R; Cancelas, JA; Spinner, RJ; Ratner, N. P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis. eLife. 2022; 11:e73511.

Chaney, KE; Perrino, MR; Kershner, LJ; Patel, AV; Wu, J; Choi, K; Rizvi, TA; Dombi, E; Szabo, S; Largaespada, DA; et al. Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST. Cancer Research. 2021; 80:4720-4730.

Heinrich, A; Bhandary, B; Potter, SJ; Ratner, N; DeFalco, T. Cdc42 activity in Sertoli cells is essential for maintenance of spermatogenesis. Cell Reports. 2021; 37:109885.

Patritti-Cram, J; Coover, RA; Jankowski, MP; Ratner, N. Purinergic signaling in peripheral nervous system glial cells. Glia. 2021; 69:1837-1851.

Thomson, CS; Pundavela, J; Perrino, MR; Coover, RA; Choi, K; Chaney, KE; Rizvi, TA; Largaespada, DA; Ratner, N. WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth. Oncogene: Including Oncogene Reviews. 2021; 40:4229-4241.

Galvin, R; Watson, AL; Largaespada, DA; Ratner, N; Osum, S; Moertel, CL. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Current Oncology Reports. 2021; 23:45.

Vélez-Reyes, GL; Koes, N; Ryu, JH; Kaufmann, G; Berner, M; Weg, MT; Wolf, NK; Rathe, SK; Ratner, N; Moriarity, BS; et al. Transposon Mutagenesis-Guided CRISPR/Cas9 Screening Strongly Implicates Dysregulation of Hippo/YAP Signaling in Malignant Peripheral Nerve Sheath Tumor Development. Cancers. 2021; 13:1584.

Weiss, BD; Wolters, PL; Plotkin, SR; Widemann, BC; Tonsgard, JH; Blakeley, J; Allen, JC; Schorry, E; Korf, B; Robison, NJ; et al. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of Clinical Oncology. 2021; 39:797-806.

Oatman, N; Dasgupta, N; Arora, P; Choi, K; Gawali, MV; Gupta, N; Parameswaran, S; Salomone, J; Reisz, JA; Lawler, S; et al. Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. Science Advances. 2021; 7:eabd7459.

Na, Y; Hall, A; Choi, K; Hu, L; Rose, J; Coover, RA; Miller, A; Hennigan, RF; Dombi, E; Kim, MO; et al. MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. Oncogene: Including Oncogene Reviews. 2021; 40:951-963.

Ma, Y; Gross, AM; Dombi, E; Pemov, A; Choi, K; Chaney, K; Rhodes, SD; Angus, SP; Sciaky, N; Clapp, DW; et al. A molecular basis for neurofibroma-associated skeletal manifestations in NF1. Genetics in Medicine. 2020; 22:1786-1793.

Asleh, J; Shofty, B; Cohen, N; Kavushansky, A; Lopez-Juarez, A; Constantini, S; Ratner, N; Kahn, I. Brain-wide structural and functional disruption in mice with oligodendrocyte-specific Nf1 deletion is rescued by inhibition of nitric oxide synthase. Proceedings of the National Academy of Sciences of USA. 2020; 117:22506-22513.

Fletcher, JS; Pundavela, J; Ratner, N. After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation. Neuro-Oncology Advances. 2020; 2:i23-i32.

Palomo-Irigoyen, M; Pérez-Andrés, E; Iruarrizaga-Lejarreta, M; Barreira-Manrique, A; Tamayo-Caro, M; Vila-Vecilla, L; Moreno-Cugnon, L; Beitia, N; Medrano, D; Fernández-Ramos, D; et al. HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. The Journal of Clinical Investigation. 2020; 130:3848-3864.

Heinrich, A; Potter, SJ; Guo, L; Ratner, N; DeFalco, T. Distinct Roles for Rac1 in Sertoli Cell Function during Testicular Development and Spermatogenesis. Cell Reports. 2020; 31:107513.

Guo, J; Chaney, KE; Choi, K; Witek, G; Patel, AV; Xie, H; Lin, D; Whig, K; Xiong, Y; Schultz, DC; et al. Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas. American Journal of Cancer Research. 2020; 10:856-869.

Gripp, KW; Schill, L; Schoyer, L; Stronach, B; Bennett, AM; Blaser, S; Brown, A; Burdine, R; Burkitt-Wright, E; Castel, P; et al. The sixth international RASopathies symposium: Precision medicine-From promise to practice. American Journal of Medical Genetics, Part A. 2020; 182:597-606.

Yokota, A; Huo, L; Lan, F; Wu, J; Huang, G. The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies. MOLECULES AND CELLS. 2020; 43:145-152.

Na, Y; Huang, G; Wu, J. The Role of RUNX1 in NF1-Related Tumors and Blood Disorders. MOLECULES AND CELLS. 2020; 43:153-159.

Yu, Y; Choi, K; Wu, J; Andreassen, PR; Dexheimer, PJ; Keddache, M; Brems, H; Spinner, RJ; Cancelas, JA; Martin, LJ; et al. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathologica. 2020; 139:157-174.

Isfort, I; Elges, S; Cyra, M; Berthold, R; Renner, M; Mechtersheimer, G; Aman, P; Larsson, O; Ratner, N; Hafner, S; et al. Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone. Scientific Reports. 2019; 9:19704.

Choi, K; Ratner, N. iGEAK: an interactive gene expression analysis kit for seamless workflow using the R/shiny platform. BMC Genomics. 2019; 20:177.

Osum, S; Stemmer-Rachamimov, A; Widemann, B; Dombi, E; Vitte, J; Dahiya, S; Rizvi, T; Ratner, N; Messiaen, L; Gutmann, D; et al. TMOD-23. PRECLINICAL DRUG EVALUATION IN A GENETICALLY ENGINEERED MINIPIG MODEL OF NEUROFIBROMATOSIS TYPE 1. Neuro-Oncology. 2019; 21:vi267.

Oatman, N; Dasgupta, N; Dasgupta, B; Choi, K; Gawali, M; Gupta, N; Parameswaran, S; Lawler, S; Brennan, C; Wu, J; et al. CBMT-05. GENETIC AND EPIGENETIC MECHANISMS REGULATING SCD INHIBITOR SENSITIVITY IN GLIOBLASTOMA. Neuro-Oncology. 2019; 21:vi33.

Ramkissoon, A; Chaney, KE; Milewski, D; Williams, KB; Williams, RL; Choi, K; Miller, A; Kalin, TV; Pressey, JG; Szabo, S; et al. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK. Clinical Cancer Research. 2019; 25:4117-4127.

Rauen, KA; Alsaegh, A; Ben-Shachar, S; Berman, Y; Blakeley, J; Cordeiro, I; Elgersma, Y; Evans, DG; Fisher, MJ; Frayling, IM; et al. First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics. American Journal of Medical Genetics, Part A. 2019; 179:1091-1097.

Rice, FL; Houk, G; Wymer, JP; Gosline, SJ C; Guinney, J; Wu, J; Ratner, N; Jankowski, MP; La Rosa, S; Dockum, M; et al. The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin. Editor, Sommer C. PloS one. 2019; 14:e0216527.

Hall, A; Choi, K; Liu, W; Rose, J; Zhao, C; Yu, Y; Na, Y; Cai, Y; Coover, RA; Lin, Y; et al. RUNX represses Pmp22 to drive neurofibromagenesis. Science Advances. 2019; 5:eaau8389.

Hennigan, RF; Fletcher, JS; Guard, S; Ratner, N. Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. Science Signaling. 2019; 12:eaau8749.

Fletcher, JS; Springer, MG; Choi, K; Jousma, E; Rizvi, TA; Dombi, E; Kim, M; Wu, J; Ratner, N. STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma. Oncogene: Including Oncogene Reviews. 2019; 38:2876-2884.

Fletcher, JS; Wu, J; Jessen, WJ; Pundavela, J; Miller, JA; Dombi, E; Kim, M; Rizvi, TA; Chetal, K; Salomonis, N; et al. Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice. JCI insight. 2019; 4:e98601.

Agresta, L; Salloum, R; Hummel, TR; Ratner, N; Mangano, FT; Fuller, C; McMasters, RL; Pater, L; Jones, BV; Szabo, S; et al. Malignant peripheral nerve sheath tumor: Transformation in a patient with neurofibromatosis type 2. Pediatric Blood and Cancer. 2019; 66:e27520.